Recommendation for hematologists in COVID-19 crisis

Recommendations FAQ

Recommendations for hematologists in COVID-19 crisis

COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients. In view of the rapidly changing evidence and general situation the EHA Scientific Working Group Infections in Hematology has developed key questions and answers on the management of cancer patients with or at risk of COVID-19.

Introduction SARS-CoV-2

Specific aspects for hematologists and oncologists


What is the risk for the patient to become infected with SARS-CoV2 and what is the risk for the patient to have a severe disease course?

What can be done to prevent COVID 19?

Who should have therapy for malignant disease deferred or interrupted?

How long should precautions last?

What diagnostic measures should be taken in somebody who shows symptoms of RTID/LRTID?

What general therapeutic measures should be taken in somebody who is infected with SARS-CoV-2?

How can COVID 19 be treated specifically?

What else should be considered?

Special aspects in pediatric hematology/oncology 

What are the symptoms in children and how similar are they to those in adult?

What is the risk of a child getting infected?

When should a child be tested and how?

Should we screen all children before chemotherapy?

Special characteristics of the pediatric infection

View patient flowcharts

  • View the ‘Patient with active cancer’ flowchart here >
  • View the ‘Patient with controlled/chronic cancer’ flowchart here >
Last Updated on Monday 20 June 2022.